Pharmaxis concludes Brochitol trial
Friday, 13 June, 2008
Pharmaxis (ASX:PXS) has completed a Phase III clinical trial of its Bronchitol inhalant spray for bronchiectasis.
The 12-month trial was an open label extension to an earlier efficacy trial and was designed to determine the adverse event profile of Bronchitol following prolonged use.
Bronchiectasis is an incurable and chronic lung condition which causes excessive mucus to build up in the lungs, making breathing difficult.
Pharmaxis intends to file a marketing application for Bronchitol after the results are published in July.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
